25 related articles for article (PubMed ID: 16973134)
1. Current Progress on the Influence Human Genetics Has on the Efficacy of Tyrosine Kinase Inhibitors Used to Treat Chronic Myeloid Leukemia.
Prakash TC; Enkemann S
Cureus; 2024 Mar; 16(3):e56545. PubMed ID: 38646295
[TBL] [Abstract][Full Text] [Related]
2. New Insights Into Cancer Chronotherapies.
Zhou J; Wang J; Zhang X; Tang Q
Front Pharmacol; 2021; 12():741295. PubMed ID: 34966277
[TBL] [Abstract][Full Text] [Related]
3. Circadian rhythms: influence on physiology, pharmacology, and therapeutic interventions.
Ayyar VS; Sukumaran S
J Pharmacokinet Pharmacodyn; 2021 Jun; 48(3):321-338. PubMed ID: 33797011
[TBL] [Abstract][Full Text] [Related]
4. Molecular Aspects of Circadian Pharmacology and Relevance for Cancer Chronotherapy.
Ozturk N; Ozturk D; Kavakli IH; Okyar A
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29039812
[TBL] [Abstract][Full Text] [Related]
5. Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment.
Lauriola M; Enuka Y; Zeisel A; D'Uva G; Roth L; Sharon-Sevilla M; Lindzen M; Sharma K; Nevo N; Feldman M; Carvalho S; Cohen-Dvashi H; Kedmi M; Ben-Chetrit N; Chen A; Solmi R; Wiemann S; Schmitt F; Domany E; Yarden Y
Nat Commun; 2014 Oct; 5():5073. PubMed ID: 25278152
[TBL] [Abstract][Full Text] [Related]
6. Chronopharmacodynamics of drugs in toxicological aspects: A short review for clinical pharmacists and pharmacy practitioners.
Erkekoglu P; Baydar T
J Res Pharm Pract; 2012 Oct; 1(2):41-7. PubMed ID: 24991588
[TBL] [Abstract][Full Text] [Related]
7. The naive airway hyperresponsiveness of the A/J mouse is Kit-mediated.
Cozzi E; Ackerman KG; Lundequist A; Drazen JM; Boyce JA; Beier DR
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12787-92. PubMed ID: 21768379
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of imatinib mesylate in neuroblastoma xenografts.
Meco D; Riccardi A; Servidei T; Brueggen J; Gessi M; Riccardi R; Dominici C
Cancer Lett; 2005 Oct; 228(1-2):211-9. PubMed ID: 15950376
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy in pediatric and adolescent oncology.
Bernstein ML
Cancer; 2011 May; 117(10 Suppl):2268-74. PubMed ID: 21523745
[TBL] [Abstract][Full Text] [Related]
10. Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice.
Nakagawa H; Takiguchi T; Nakamura M; Furuyama A; Koyanagi S; Aramaki H; Higuchi S; Ohdo S
Biochem Pharmacol; 2006 Nov; 72(10):1237-45. PubMed ID: 16973134
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
[TBL] [Abstract][Full Text] [Related]
12. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
[TBL] [Abstract][Full Text] [Related]
13. Chronopharmacology of antitumor effect induced by interferon-beta in tumor-bearing mice.
Takane H; Ohdo S; Yamada T; Yukawa E; Higuchi S
J Pharmacol Exp Ther; 2000 Aug; 294(2):746-52. PubMed ID: 10900256
[TBL] [Abstract][Full Text] [Related]
14. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
15. Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate.
Ogawa Y; Kawamura T; Furuhashi M; Tsukamoto K; Shimada S
J Dermatol Sci; 2008 Sep; 51(3):190-9. PubMed ID: 18485676
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
